Sevda Önder1, Murat Ozturk2. 1. Department of Dermatology, Ordu University Medical Faculty, Ordu, Turkey. 2. Department of Dermatology, Van Training and Research Hospital, Health Sciences University, Van, Turkey.
Abstract
Purpose: The aim of this study was to evaluate the effect of omalizumab on immunoinflammatory cells in patients with chronic spontaneous urticaria (CSU).Material and methods: The study was designed retrospectively. Seventy-four patients diagnosed with CSU and taking omalizumab between 2016 and 2019 were included in this study. Hematological parameters of the patients before treatment and after 12 weeks of treatment were recorded. Lymphocyte/monocyte ratio (LMR), neutrophil/monocyte ratio (NMR), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) were examined and the effects of omalizumab treatment on inflammatory parameters were evaluated. Angioedema status of patients, total IgE levels and the relationship between these variables were investigated. The results were evaluated statistically. Results: The neutrophil count, the neutrophil/lymphocyte ratio and neutrophil/monocyte ratio showed a statistically significant reduction after 12 weeks of omalizumab treatment. There was no significant change in other data. Conclusion: In our study, omalizumab treatment significantly reduced neutrophil/lymphocyte ratio and neutrophil/monocyte ratio. Further studies are needed to assess the correlation between treatment response and these parameters to determine the likelihood of a decrease in these values by the antiinflammatory effect of omalizumab.
Purpose: The aim of this study was to evaluate the effect of omalizumab on immunoinflammatory cells in patients with chronic spontaneous urticaria (CSU).Material and methods: The study was designed retrospectively. Seventy-four patients diagnosed with CSU and taking omalizumab between 2016 and 2019 were included in this study. Hematological parameters of the patients before treatment and after 12 weeks of treatment were recorded. Lymphocyte/monocyte ratio (LMR), neutrophil/monocyte ratio (NMR), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) were examined and the effects of omalizumab treatment on inflammatory parameters were evaluated. Angioedema status of patients, total IgE levels and the relationship between these variables were investigated. The results were evaluated statistically. Results: The neutrophil count, the neutrophil/lymphocyte ratio and neutrophil/monocyte ratio showed a statistically significant reduction after 12 weeks of omalizumab treatment. There was no significant change in other data. Conclusion: In our study, omalizumab treatment significantly reduced neutrophil/lymphocyte ratio and neutrophil/monocyte ratio. Further studies are needed to assess the correlation between treatment response and these parameters to determine the likelihood of a decrease in these values by the antiinflammatory effect of omalizumab.